Page 16 - Crispr News Today

A new gene editing method uses the CRISPR technique to modify the cells of an organ in vivo, creating a mosaic used to identify the effects of each altered gene. Scientists from the Swiss Federal Institute of Technology (ETH) in Zürich developed this technology called AAV-Perturb-seq, based on adeno-associated virus (AAV) to target, edit and analyze single-cell genetic perturbations.

In this interview conducted at SLAS EU 2023 in Brussels, Belgium, we spoke to Ulrike Kuenzel, Associate Director in the Functional Genomics department at AstraZeneca about the application of arrayed CRISPR screening for target identification and more.

As ‘citrus greening’ devastates the state’s orange industry, growers are exhausted and giving into the temptation of booming land prices

1. In this randomized controlled trial, infusion of OTQ923 disrupted inhibitory HBG1 and HBG2 promoter regions of the gamma-globin gene. 2. This disruption resulted in sustained production of fetal hemoglobin and improved symptoms of severe sickle cell disease (SCD). Evidence Rating Level: 2 (Good) Study Rundown: SCD is caused by mutations disrupting the function of

InnovationRx is your weekly digest of healthcare news. Sign up!

Scientists have established the effectiveness of vaccines they developed to prevent the disfiguring skin disease leishmaniasis in animal studies, and Phase 1 human trial planning is in motion for the most promising candidate.

InnovationRx is your weekly digest of healthcare news. Sign up!

Researchers evaluated the use of a dual clustered regularly interspaced short palindromic repeats (CRISPR)-Cas3 system.

InnovationRx is your weekly digest of healthcare news. Sign up!

Kevin Davies, PhD, executive editor, The CRISPR Journal and GEN Biotechnology, and author of Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing, discusses the difficulties inherent in making CRISPR gene editing technology an equitable treatment.